Psychedelic Stocks

2020-06-22 Jeff Nielson

Psychedelics micro-dosing offers several key advantages over psychedelic drug applications centered around heavier dosages.

2020-06-19 Jeff Nielson

ATAI Life Sciences is preparing to add three new drug development partners as it builds the premier R&D platform in the psychedelics space.

2020-06-19 TSI Reporter

PharmaDrug adds depth to its board with new Director who has a wealth of healthcare and addiction-therapy experience.

2020-06-09 TSI Editor

As rumors swirl about Compass Pathways going public, this could become the first psychedelics Unicorn.

2020-06-08 TSI Reporter

MindMed begins a Phase 2 clinical trial of LSD for cluster headaches in Switzerland.

2020-06-08 TSI Reporter

Champignon Brands has added a new contact research organization (CRO) to advance its IP portfolio.

2020-06-05 TSI Reporter

AlphaMind Brands Inc is entering the functional mushrooms market.

2020-06-04 TSI Reporter

MindMed has high hopes for its new LSD-based anxiety therapy.

2020-06-03 TSI Reporter

Numinus adds to its management team.

2020-06-02 TSI Reporter

MindMed's Microdosing Division is expanding its ADHD clinical trial.

2020-05-29 TSI Reporter

Certain shareholders have agreed to a voluntary resale restriction that covers 17.8 million shares.

2020-05-28 TSI Reporter

Newly-listed Numinus Wellness provides a corporate update.